![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
BeerYaakov Mental Health Center |
---|---|
Information provided by: | BeerYaakov Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00465283 |
This is a double blind randomized investigation of donepezil for patients suffering from schizophrenia, undergoing ECT.
Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether donezepil has a protective effect on memory disfunction, while patients are treated with ECT. Several parameters will be invistigated at baseline: general psychopathological measures, memory function scales, side effects scales. The same measurements will be taken throughout the trial and one month after ending the ECT.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Schizoaffective Disorder Schizophreniform Disorder |
Drug: Donezepil |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Donepezil Double Blind Trial for ECT Memory Disfunction |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Tali Nachshoni, MD | 972-8-9258372 | bynachshoni@beer-ness.health.gov.il |
Contact: Marina Kupchik, MD | 972-89258382 | kupchik@beer-ness.health.gov.il |
Israel | |
Beer Yaakov MHC | |
Beer Yaacov, Israel, 70350 |
Principal Investigator: | Tali Nachshoni, MD | Beer Yaakov Mental Health Center |
Study ID Numbers: | Donepezil-180CTIL |
Study First Received: | April 22, 2007 |
Last Updated: | April 22, 2007 |
ClinicalTrials.gov Identifier: | NCT00465283 |
Health Authority: | Israel: Ministry of Health |
Donepezil, ECT, Memory Disfunction |
Schizophrenia Signs and Symptoms Mental Disorders Donepezil Neurologic Manifestations |
Psychotic Disorders Neurobehavioral Manifestations Memory Disorders Schizophrenia and Disorders with Psychotic Features |
Nootropic Agents Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Enzyme Inhibitors |
Cholinergic Agents Pharmacologic Actions Cholinesterase Inhibitors Pathologic Processes Therapeutic Uses Central Nervous System Agents |